Anantha Shekhar
Indiana University School of Medine/CTSI · Indiana University School of Medicine/CTSI · Indiana University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
5
all conditions, ClinicalTrials.gov
NIH grants tied to them
14
1 more share only the name and are not shown
Trial papers
18
PubMed author-name match
Trials
Studies that name Anantha Shekhar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:40 UTC. Open this list on ClinicalTrials.gov
- N/ANCT01386801 · Multicenter Research Study to Build a Repository to Study Chronic Diseases in IndianaFairbanks Institute · active not recruiting · Diabetes Mellitus Type II · principal investigator
- N/ANCT00741416 · Biorepository: Indiana Health StudyFairbanks Institute · unknown · Coronary Artery Disease, Heart Disease, Healthy · principal investigator
- Ph2NCT00235274 · Effects of RG1068 (Secretin) on Information Processing in SchizophreniaIndiana University · completed · Schizophrenia · principal investigator
- Ph3NCT00216281 · Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant SchizophreniaIndiana University · terminated · Schizophrenia · principal investigator
- Ph2NCT00216294 · Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive DisorderIndiana University · completed · Obsessive Compulsive Disorder (OCD) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Indiana Clinical and Translational Sciences InstituteUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2018 to 2019 · $5,264,717 awarded in 2019Same name and institution; not confirmed by an ID
- Indiana Clinical and Translational Sciences InstituteKL2TR001106 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2013 to 2017 · $691,040 awarded in 2017Same name and institution; not confirmed by an ID
- Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2013 to 2017 · $5,297,754 awarded in 2017Same name and institution; not confirmed by an ID
- Indiana Clinical and Translational Sciences InstituteTL1TR001107 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2013 to 2017 · $304,098 awarded in 2017Same name and institution; not confirmed by an ID
- Neurobiology of Anxiety and Panic DisordersR01MH052619 · NIMH · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 1996 to 2016 · $389,835 awarded in 2016Same name and institution; not confirmed by an ID
- Inhibition of nNOS-PSD95 interactions: A novel approach to developing treatmentsR21MH104018 · NIMH · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2014 to 2015 · $195,000 awarded in 2015Same name and institution; not confirmed by an ID
- Indiana Clinical and Translational Science Institute (UL1)UL1TR000006 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2012 to 2013 · $1,205,189 awarded in 2013Same name and institution; not confirmed by an ID
- Indiana Clinical and Translational Science Institute-K12 ProgramKL2TR000163 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2012 to 2013 · $176,809 awarded in 2013Same name and institution; not confirmed by an ID
- Indiana Clinical and Translational Science Institute-T32 Program TL1TL1TR000162 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2012 to 2013 · $81,867 awarded in 2013Same name and institution; not confirmed by an ID
- Role of Serotonin and CRF Pathways in Anxiety and HPA RegulationsR01MH065702 · NIMH · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2003 to 2013 · $326,642 awarded in 2013Same name and institution; not confirmed by an ID
- CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2008 to 2011 · $617,452 awarded in 2011Same name and institution; not confirmed by an ID
- Indiana Clinical and Translational Science Institute-K12 ProgramKL2RR025760 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2008 to 2011 · $543,231 awarded in 2011Same name and institution; not confirmed by an ID
- Indiana Clinical and Translational Science Institute-T32 Program TL1TL1RR025759 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 2008 to 2011 · $179,792 awarded in 2011Same name and institution; not confirmed by an ID
- NEUROBIOLOGICAL SUBSTRATES OF ANXIETY & PANIC DISORDERR29MH045362 · NIMH · INDIANA UNIVERSITY INDIANAPOLIS · fiscal years 1989 to 1993 · $113,707 awarded in 1993Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:40 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.Am J Psychiatry · 2008471 citationsRCR 13.1
- Auditory event-related potential abnormalities in bipolar disorder and schizophrenia.Int J Psychophysiol · 2004144 citationsRCR 4.1
- Haloperidol impairs learning and error-related negativity in humans.J Cogn Neurosci · 2004138 citationsRCR 3.7
- Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.Depress Anxiety · 2010135 citationsRCR 4.3
- Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.Schizophr Bull · 200885 citationsRCR 2.9
- Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.J Clin Psychiatry · 200868 citationsRCR 2.4
- Eyeblink conditioning deficits indicate timing and cerebellar abnormalities in schizophrenia.Brain Cogn · 200556 citationsRCR 1.6
- Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.J Clin Psychiatry · 200550 citationsRCR 1.7
- 42 citationsRCR 1.5
- Eyeblink conditioning anomalies in bipolar disorder suggest cerebellar dysfunction.Bipolar Disord · 200941 citationsRCR 1.3